Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Zymeworks nets $59.2mm through initial public offering in US and Canada

Executive Summary

Zymeworks Inc. (Canadian biotech developing multifunctional therapeutics for cancer) netted $59.2mm through its initial public offering of 4.9mm shares (including partial exercise of the overallotment) at $13. The company will list on both the New York Stock Exchange and the Toronto Stock Exchange.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies